Skip to main content
Premium Trial:

Request an Annual Quote

ABL Inks Marketing Deal with Abbott for HIV Genotyping Data Analysis Software

NEW YORK (GenomeWeb) – Advanced Biological Laboratories announced it has granted Abbott non-exclusive rights to sell its HIV genotypic data analysis software suite.

Abbott will market ABL's data analysis software to its customers within the US, the largest market in the world for HIV genotyping for diagnostic use and in clinical trials. ABL, based in Luxembourg, is aiming to expand the presence and use of its products in the US market, CEO Chalom Sayada said in a statement.

Abbot is a leading player in the HIV genotyping market with its RealTime HIV-1 test. The diagnostic gauges levels of all viral groups and subtypes and is readily used in studies run by entities such as AIDS Clinical Trials Group and International Maternal Pediatric Adolescent AIDS Clinical Trials Group.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.